Active Ingredient(s): Guselkumab
FDA Approved: * July 13, 2017
Pharm Company: * JANSSEN BIOTECH
Category: Immunosuppressive

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Tremfya Overview

Guselkumab is a monoclonal antibody.[1] By targeting the IL-23 subunit alpha (p19 subunit)[2] (which is not part of IL-12) guselkumab was designed to block interleukin-23 but not IL-12. Guselkumab was developed by Janssen Global Services, LLC. In July 2017 it gained US FDA approval for treatment of plaque psoriasis.[3][4] It is branded as Tremfya.[4][3] It has undergone phase III clinical trials comparing it with ustekinumab and adalimumab.[4] See also Ustekinumab, a monoclonal antibody ta...

Read more Tremfya Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Tremfya Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 100mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Tremfya: (1 result)

Sorted by National Drug Code
  • 57894-640 Tremfya 100 mg/ml Subcutaneous Injection by Janssen Biotech, Inc.

Other drugs which contain Guselkumab or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 21 November 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.